Buscar resultados de ensayos clínicos
Hematologic Neoplasms - 25 Studies Found
Estado | Estudiar |
Recruiting |
Nombre del estudio: Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors Condición: Hematologic Neoplasms Fecha: 2011-06-15 Intervenciones:
|
Not yet recruiting |
Nombre del estudio: Prophylactic Early PN in HPT/BMT Condición: Hematologic Neoplasms Fecha: 2017-03-08 Intervenciones:
|
Recruiting |
Nombre del estudio: A Study Comparing the Efficacy of Intravenous Followed by Oral Itraconazole With Intravenous Caspofungin For Empiric Antifungal Therapy in Neutropenic Participants With Hematological Malignancy Condición: Hematologic Neoplasms Fecha: 2016-09-06 Intervenciones:
|
Recruiting |
Nombre del estudio: Platelet Transfusion Requirements in Hematopoietic Transplantation Condición: Hematologic Neoplasms Fecha: 2016-01-06 Intervenciones: Drug: Tranexamic Acid |
Recruiting |
Nombre del estudio: Studyof Allogeneic Hematopoietic Stem Cell Transplantation From One Haplotype Mismatch Related Donor or From an Unrelated Donor in Elderly Patients Condición: Hematologic Neoplasms Fecha: 2015-11-30 Intervenciones: Procedure: Allogeneic (Allo) hematopoietic stem cell transplantation |
Recruiting |
Nombre del estudio: Use of Haploidentical Related Donors for Patients Without Matched Sibling, Unrelated Donor or Cord Blood Units Condición: Hematologic Neoplasms Fecha: 2015-07-17 Intervenciones: Procedure: T-Cell replete haplo-transplant Infusion of haploidentical related donor peripheral blood ste |
Recruiting |
Nombre del estudio: Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Condición: Hematologic Neoplasms Fecha: 2015-05-18 Intervenciones:
|
Recruiting |
Nombre del estudio: Safety Study of Anti-LAG-3 in Relapsed or Refractory Hematologic Malignancies Condición: Hematologic Neoplasms Fecha: 2014-02-12 Intervenciones:
|
Active, not recruiting |
Nombre del estudio: Phase 1/2 Study of AG-221 in Subjects With Advanced Hematologic Malignancies With an IDH2 Mutation Condición: Hematologic Neoplasms Fecha: 2013-07-31 Intervenciones: Drug: AG-221 AG-221 administered orally on every day of 28 day cycles until disease progression or unacc |
Active, not recruiting |
Nombre del estudio: Feasibility Study of Genomic Sequencing to Find Potential Targets for Personalized Therapy Condición: Hematologic Neoplasms Fecha: 2013-05-28 |